Edison issues review on Worldwide Healthcare Trust

RNS Number : 0244Z

Worldwide Healthcare Trust PLC

07 January 2020

 

London, UK, 7 January 2020

Edison issues review on Worldwide Healthcare Trust (WWH)

Worldwide Healthcare Trust (WWH) is managed by Sven Borho and Trevor Polischuk at OrbiMed. They remain very constructive on the prospects for the global healthcare sector - despite headline risk ahead of the 2020 US presidential election - citing industry innovation, which they suggest is at 'unparalleled' levels, and has historically been an important driver of the sector's performance. Although investor concerns about drug pricing in the US remain, Borho and Polischuk say that pharma and biotech companies are 'still getting paid and are generating attractive returns'. In addition to opportunities in developed markets, they are also finding interesting investment ideas in China, due to higher product approval standards and a relaxation of listing requirements for fledgling companies.

WWH's shares regularly trade close to NAV (the board targets a maximum discount of 6%). The trust's current 0.4% premium to cum-income NAV compares with an average premium of 0.1% over the last three years, and average discounts of 0.1%, 2.0% and 4.3% over the last one, five and 10 years respectively. While WWH is managed for capital growth, it also pays regular six-monthly dividends, and currently yields 0.9%.  

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, [phone]

Sarah Godfrey, [phone]

[e-mail]

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-investment-research 

Twitter           www.twitter.com/Edison_Inv_Res 

YouTube       www.youtube.com/edisonitv 

 

END

 

 

NRABRMTTMTTMBIM